
## Site Map

Universitätsmedizin Mainz



### Registration required!!!

Please register **until 12th of September 2023** at https://survey.zdv.uni-mainz.de/index.php/838875



Organisation
Dr. Ann-Kathrin Herrmann
Scientific Coordinator UCT Mainz

Phone: +49 (0) 6131 - 175487 Email: uct-science@uct-mainz.de



The UCT Mainz presents

# 5th Mini-Symposium in Translational Oncology (MiTraC)

Enhancing Cancer Immunotherapy: New Targets, New Drugs, New Partners

19th of September 2023 | 1.00 - 6.00 pm



**uct** | Universitäres Centrum für Tumorerkrankungen MAINZ

The UCT Mainz presents

# 5th Mini-Symposium in Translational Oncology (MiTraC)

#### Dear friends & colleagues,

we are happy to welcome you to the 5th UCT Mainz Mini-Symposium in Translational Oncology (MiTraC) sponsored by Merck KGaA.

In this Mini-Symposium series we aim to address important areas of cancer research linked to translational oncology. Within this format, we have the opportunity to invite outstanding scientists to present novel findings, techniques and ideas.

The topic of this year's symposium is "Enhancing Cancer Immunotherapy: New Targets, New Drugs, New Partners", focussing on the prominent scientific core area of the UCT Mainz - Immuno-Oncology. The talks will cover major topics of many research groups working at the UCT Mainz and our partnering institutions and clinics.

We wish you a pleasant time and an interesting symposium with lots of new insights and discoveries!

With best regards,

Thomas Kindler Head of the UCT Mainz

Ann-Kathrin Herrmann Scientific Coordinator UCT Mainz

Sponsored by





### **Program**

#### 13.00 Uhr Welcome

Session 1: Cellular components of immune response

and beyond

Chair: Claudia Paret, Mainz

13.05 Uhr Harnessing natural killer cells against solid tumors

Adelheid Cerwenka, Mannheim

13.40 Uhr Divergent roles of eosinophils and neutrophils in breast cancer

Hannah Garner, Amsterdam

14.15 Uhr CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours

Thomas Tüting, Magdeburg

14.50 Uhr Foreignization of Tumor Antigens and Cross-Reactivity with Infectious Agents to Improve Vaccination Approaches

Roland Martin, Zurich

#### 15.25 Uhr Coffee Break & Networking

Session 2: Novel strategies to enhance anti-tumor

immune response

Chair: Sebastian Försch, Mainz

16.10 Uhr Targeting TBK1 to overcome resistance to cancer immunotherapy

Russell Jenkins, Boston

16.45 Uhr IMMUcan consortium: molecular and spatial cellular data to inform next generation immunotherapies

Henoch Hong, Darmstadt

17.20 Uhr Creating MHC-restricted neoantigens with covalent inhibitors and targeting them by immune therapy

Shohei Koide, New York